scanance.
Sign inGet Premium
PM

Pro Medicus Limited

PME.AXHealthcareASX

Health Information Services · Last scanned May 30, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$212.9M
+31.9% YoY
Net Income
$115.2M
+39.2% YoY
EBITDA
$164.8M
+36.6% YoY
Free Cash Flow
$102.7M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Pro Medicus Limited

Part of the healthcare sector, Pro Medicus Limited (PME.AX) is listed under Health Information Services. At a $13.82B market cap, Pro Medicus Limited ranks as a large-cap company within healthcare. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software.

Key stats
Market Cap$13.82B
P/E (TTM)59.04
Fwd P/E71.01
EPS$2.25
Beta0.59
52W Change-53.1%
Dividend Yield0.48%
ROE76.8%
Analysis

Pro Medicus Limited holds $221.8M in cash against $2.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $102.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 76.8% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 27.0% further supports the picture of efficient asset utilization. Revenue has grown from $93.4M (2022) to $212.9M (2025), reflecting a 128% increase over the period.

PME.AX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, PME.AX has financial flexibility that may help navigate uncertain periods. At over 50x earnings, PME.AX carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PME.AX.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms